Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given a consensus rating of “Buy” by the twenty-four analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $125.72.
EW has been the subject of several research analyst reports. Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $130.00 target price (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Canaccord Genuity reiterated a “buy” rating and set a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 25th. Jefferies Group LLC upped their target price on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st.
Edwards Lifesciences Corporation (NYSE:EW) traded down $0.01 during mid-day trading on Thursday, reaching $107.09. 1,071,667 shares of the company traded hands, compared to its average volume of 1,910,742. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 1 year low of $81.12 and a 1 year high of $121.45. The company has a market cap of $22,662.38, a PE ratio of 29.67, a PEG ratio of 1.92 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same quarter last year, the firm earned $0.68 EPS. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. equities research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,540 shares of company stock valued at $17,130,243. Company insiders own 2.13% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. ETF Managers Group LLC acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter worth $112,000. Shine Investment Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences Corporation during the 2nd quarter worth about $126,000. Cornerstone Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares during the last quarter. Alexandria Capital LLC boosted its stake in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new position in shares of Edwards Lifesciences Corporation during the 2nd quarter worth about $140,000. 82.16% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/11/19/edwards-lifesciences-corporation-ew-receives-125-72-average-price-target-from-analysts.html.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.